SCHEMBL10107587

SCHEMBL10107587

CC(C)[C@H]1CCCC[C@@H]1OC(=O)N1CCC(OCc2nc(-c3ccncc3)no2)CC1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.67
LMNA P02545 6/20 0.43
TSHR P16473 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
RECQL P46063 2/20 0.41
CHRNA7 P36544 1/20 0.39
KMT2A Q03164 1/20 0.37
MAPK1 P28482 1/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
HRH3 Q9Y5N1 2/20 0.37
RAB9A P51151 3/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
NPC1 O15118 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL389022 0.89 GPR119 (0.64) GPR119LMNATSHRSMN1; SMN2CHRNA7
SCHEMBL391232 0.89 GPR119 (0.64) GPR119LMNATSHRSMN1; SMN2CHRNA7
SCHEMBL1843803 0.89 GPR119 (0.64) GPR119LMNATSHRSMN1; SMN2CHRNA7
SCHEMBL390687 0.86 GPR119 (0.74) GPR119LMNATSHRSMN1; SMN2RECQL
SCHEMBL390101 0.86 GPR119 (0.73) GPR119LMNATSHRSMN1; SMN2RECQL
SCHEMBL386190 0.84 GPR119 (0.76) GPR119LMNATSHRSMN1; SMN2RECQL
SCHEMBL387143 0.83 GPR119 (0.80) GPR119LMNATSHRSMN1; SMN2RECQL
SCHEMBL388852 0.82 GPR119 (0.73) GPR119LMNATSHRSMN1; SMN2RECQL
SCHEMBL389587 0.82 GPR119 (0.79) GPR119LMNATSHRSMN1; SMN2RECQL
SCHEMBL389342 0.80 GPR119 (0.70) GPR119LMNATSHRSMN1; SMN2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207147-B2 Heterocyclic derivatives as GPCR receptor agonists PROSIDION LIMITED (GB) 2012-06-26 US disclosed
US-20090281060-A1 HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281060-A1 HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS GPR119, GCGR, GLP1R GPR119 1/4885LMNA 4276/4885TSHR 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.